Idarubicina Accord

Idarubicin, the active ingredient in Idarubicina Accord, is an anthracycline presented as an injection solution for intravenous use. It is employed in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia in both adult and pediatric patients, and is administered under strict clinical protocols to maximize therapeutic benefit while monitoring for toxicity.

GNH USA supplies Idarubicina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across EU and global markets.

Idarubicin is an anthracycline chemotherapy used in the management of acute leukemias.

Acute myeloid leukemia: induces remission by intercalating DNA and inhibiting topoisomerase II in leukemic blasts. Acute lymphoblastic leukemia: achieves disease control through DNA damage and apoptosis of malignant lymphoid cells. Relapsed or refractory AML: provides a therapeutic option when standard regimens have failed.

Idarubicina Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (decreased blood cell counts) - Mucositis (inflammation of the mouth lining) - Fatigue - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity, including reduced left‑ventricular function - Severe neutropenia and febrile neutropenia - Hemorrhagic events due to thrombocytopenia - Anaphylactic or hypersensitivity reactions - Secondary malignancies such as therapy‑related leukemia - Acute liver injury

Prior to initiating therapy, clinicians should assess patient‑specific risk factors and monitor organ function throughout treatment.

Cardiac assessment: baseline and periodic echocardiograms to detect early cardiotoxicity. Hematologic monitoring: regular complete blood counts to manage myelosuppression. Liver function: evaluate hepatic enzymes before each cycle. Renal function: assess creatinine clearance for dose adjustments. Concomitant cardiotoxic agents: avoid or limit use of other anthracyclines and radiation to the chest. Pregnancy and lactation: contraindicated; use only if benefits outweigh risks. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Idarubicina may interact with several medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Concurrent use of other anthracyclines or cardiotoxic chemotherapy agents. - Live vaccines administered during treatment due to immunosuppression. - High‑dose radiation therapy to the thoracic region.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., azole antifungals) that may increase plasma levels. - Anticoagulants, as thrombocytopenia can heighten bleeding risk. - Drugs that prolong QT interval, potentially exacerbating cardiac effects.